Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1238 - Population-based use of intravenous bisphosphonates in patients newly diagnosed with symptomatic multiple myeloma in Denmark in 2005-2015: impact of patient characteristics

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Multiple Meyloma

Presenters

Vera Ehrenstein

Citation

Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286

Authors

V. Ehrenstein1, A.G. Ording1, S.P. Ulrichsen1, I.T. Andersen1, A. Seesaghur2, C. Helleberg3, T. Silkjær4, R. Hernandez5, D. Niepel6, N. Abildgaard7

Author affiliations

  • 1 Department Of Clinical Epidemiology, Aarhus University Hospital, 8200 - Aarhus/DK
  • 2 Amgen Limited, Amgen Limited, CB4 0WD - Cambridge/GB
  • 3 Department Of Hematology, Herlev Hospital, 2730 - Herlev/DK
  • 4 Department Of Hematology R, Thg, Aarhus University Hospital, 8000 - Aarhus/DK
  • 5 Center For Observational Research, Amgen Inc., 91320 - Thousand Oaks/US
  • 6 Amgen Gmbh, Amgen GmbH, 6301 - Zug/CH
  • 7 Department Of Hematology X, Odense University Hospital, 5000 - Odense/DK
More

Resources

Abstract 1238

Background

Bone and kidneys are among the main affected organ systems in symptomatic multiple myeloma (MM) and may be associated with debilitating complications. Thus, bone health and renal protection are at the core of MM management. Bisphosphonates (BP) are recommended for prevention of bone complications in all newly diagnosed symptomatic MM patients, but BPs are also potentially nephrotoxic and are cleared by the kidneys. This study describes the routine clinical use of BP among MM patients in Denmark.

Methods

Adult patients newly diagnosed with MM between 01.01.2005 and 30.06.2015 were identified in the Danish National Multiple Myeloma Registry, and information on BP treatment in first-line (1L) anti-MM therapy was analyzed.

Results

Among 2,633 MM patients with information on BP treatment in 1L, 1,838 (69.8%) received BP. Median time from MM diagnosis to BP treatment was 19 days (IQR: 9, 35). Receipt of BP among 1L-treated patients by therapy was: 79.4% (635/799) in autologous stem cell transplant recipients, 75.0% (793/1,058) in patients treated with conventional chemotherapy, and 70.2% (903/1,286) in those treated with bortezomib-, lenalidomide-, or thalidomide-containing regimens. Among the BP-treated patients, 67.2% (543/1,838) had no recorded hypercalcemia at MM diagnosis, 81.0% (1,489/1,838) had a record of skeletal-related events (SRE) in the 12 months before MM diagnosis, and 80.0% (1,470/1,838) had a record of osteolytic foci at 1L. An additional 431 patients had a record of osteolytic foci but no record of BP treatment. Patients without a record of BP treatment had higher prevalence of overall hospital-registered comorbidity, anemia, or higher ISS stage at MM diagnosis than patients with a record of BP treatment. Severe renal impairment (stages 4 - 5) was recorded at MM diagnosis in 31.8% of patients with no BP record and in 12.6% of patients with BP record at 1L start.

Conclusions

In newly diagnosed MM patients receiving 1L, co-administration of BP and anti-MM therapy is widespread, though less prevalent in patients with renal impairment or comorbidity burden.

Clinical trial identification

Legal entity responsible for the study

Aarhus University.

Funding

This study was funded by Amgen Inc. via institutional research grant to and administered by Aarhus University.

Editorial Acknowledgement

Disclosure

V. Ehrenstein, A.G. Ording, S.P. Ulrichsen: Employee of Aarhus University. I.T. Andersen, C. Helleberg, T. Silkjær, N. Abildgaard: Employee of the listed institution. A. Seesaghur, R. Hernandez, D. Niepel: Employee and stockholder: Amgen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.